Fig. 2

Hsa_circ_0004085 level in the plasma of CRC patients was correlated with the response to oxaliplatin/5-FU. A Hsa_circ_0004085 levels in tumor tissues and preoperative plasma of CRC patients were determined, and the correlation between them was analyzed. B Hsa_circ_0004085 levels in CRC cells and culture media were determined, and the correlation between them was analyzed. C Hsa_circ_0004085 levels in the preoperative plasma of CRC patients and in the plasma of healthy donors were measured by qRT-PCR. D Hsa_circ_0004085 levels in the plasma of CRC patients before surgery, after surgery, and after tumor recurrence were measured by qRT-PCR. E Hsa_circ_0004085 levels in the pretherapy plasma of CRC patients with different responses to chemotherapy were determined by qRT-PCR. F The median hsa_circ_0004085 level was used as the cut-off, and the effect of hsa_circ_0004085 in pretherapy plasma on PFS in CRC patients treated with XELOX or FOLFOX was analyzed using KM methods. (*P < 0.05, **P < 0.01, ***P < 0.001, NS: not signifcant)